Dijokaite-Guraliuc, Aiste, Das, Raksha, Zhou, Daming, Ginn, Helen M., Liu, Chang, Duyvesteyn, Helen M.E., Huo, Jiandong, Nutalai, Rungtiwa, Supasa, Piyada, Selvaraj, Muneeswaran, and others. (2023) Rapid escape of new SARS-CoV-2 Omicron variants from BA.2 directed antibody responses. Cell Reports, 42 (4). Article Number 112271. ISSN 2211-1247. (doi:10.1016/j.celrep.2023.112271) (KAR id:100432)
|
PDF
Publisher pdf
Language: English 
This work is licensed under a Creative Commons Attribution 4.0 International License.
|
|
|
Download this file (PDF/9MB) |
Preview |
| Request a format suitable for use with assistive technology e.g. a screenreader | |
|
PDF
Author's Accepted Manuscript
Language: English 
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
|
|
|
Download this file (PDF/25MB) |
Preview |
| Request a format suitable for use with assistive technology e.g. a screenreader | |
| Official URL: https://doi.org/10.1016/j.celrep.2023.112271 |
|
Abstract
In November 2021 Omicron BA.1, containing a raft of new spike mutations emerged and quickly spread globally. Intense selection pressure to escape the antibody response produced by vaccines or SARS-CoV-2 infection then led to a rapid succession of Omicron sub-lineages with waves of BA.2 then BA.4/5 infection. Recently, many variants have emerged such as BQ.1 and XBB, which carry up to 8 additional RBD amino-acid substitutions compared to BA.2. We describe a panel of 25 potent mAbs generated from vaccinees suffering BA.2 breakthrough infections. Epitope mapping shows potent mAb binding shifting to 3 clusters, 2 corresponding to early-pandemic binding hotspots. The RBD mutations in recent variants map close to these binding sites and knock out or severely knock down neutralization activity of all but 1 potent mAb. This recent mAb escape corresponds with large falls in neutralization titre of vaccine or BA.1, BA.2 or BA.4/5 immune serum.
| Item Type: | Article |
|---|---|
| DOI/Identification number: | 10.1016/j.celrep.2023.112271 |
| Additional information: | For the purpose of open access, the author(s) has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising. |
| Uncontrolled keywords: | SARS-CoV-2, BA.2, variant, mutation, RBD, antibodies, binding site, breakthrough, neutralizing, structure, COVID-19, CP: Immunology, CP: Microbiology |
| Subjects: | Q Science > QR Microbiology > QR355 Virology |
| Divisions: | Divisions > Division of Natural Sciences > Medway School of Pharmacy |
| Funders: |
Wellcome Trust (https://ror.org/029chgv08)
British Heart Foundation (https://ror.org/02wdwnk04) National Institute for Health Research (https://ror.org/0187kwz08) Medical Research Council (https://ror.org/03x94j517) |
| Depositing User: | Nigel Temperton |
| Date Deposited: | 11 Mar 2023 14:45 UTC |
| Last Modified: | 05 Nov 2024 13:05 UTC |
| Resource URI: | https://kar.kent.ac.uk/id/eprint/100432 (The current URI for this page, for reference purposes) |
University of Kent Author Information
Temperton, Nigel.
| Creator's ORCID: |
 https://orcid.org/0000-0002-7978-3815
|
|---|---|
| CReDIT Contributor Roles: |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):
Altmetric
Altmetric
